Cannabis Health speaks to Kiran Sidhu, CEO of Halo Labs, about the African cannabis sector, the impact of COVID-19 and his predictions for 2021.
According to BDS Analytics, the data partner for the US National Cannabis Industry Association, Halo is the top company in the state of Oregon for sales of cannabis flower, number three for concentrates and pre-rolls.
The growing company has expanded to the UK (with the acquisition of CanMart) and Lesotho, a small country located just south of Johannesburg. Lesotho is the first African country to legalise the cultivation and manufacturing of medical cannabis and one of the world’s most sought-after locations for cannabis production.
Halo’s cultivation site in Lesotho is operated by Bophelo Bioscience, a holder of one of a limited number of licences issued in the country.
Following a series of high-value acquisitions – including the UK’s CanMart and Oregon-based company, Winberry Farms – the company has experienced a rapid growth in sales in 2020. This week, the company reported a 32 percent year over year growth in the state of Oregon, with retail sales reaching $89.9 million in November 2020.
Sidhu tells us about the origins of Halo Labs, the company’s expansion to the UK and its growing operations in the African cannabis sector.
CH: Tell us about the origins of Halo Labs and your journey as a company.
KS: Halo labs started in 2017 in Andreas Met’s [co-founder of Halo] chicken coop. At the time, we were known in the industry as blasters, so effectively we took raw cannabis, put them in butane and then through that process we made vaporiser cartridges.
Now we span four countries, the UK, Lesotho, the United States and soon Canada. We make about 10 products in the state of Oregon and we’re growing in California – we’re working on building a very large cultivation site, which is the largest in Northern California.
In Lesotho, Louisa [Mojela], our chairperson, founded Bophelo Bioscience, which is arguably one of the largest grows in the world in terms of licensed space.
I view Halo, in a strange way, as two distinct businesses. It’s one that is North American, which is much more recreationally focused and it’s one that is outside North America, which is what we call a seed to sale distribution system, from Lesotho to Malta and then from Malta onward into the UK.
CH: What are some of the main challenges of working in the cannabis sector?
KS: A lot of people look at cannabis as this sexy business, like something technological. But really, at the end of the day, cannabis is a bricks and mortars, manufacturing, cultivation business.
It’s extremely working capital intensive without the ability, at least in the US, to access bank lines because banking isn’t available to us.
In a strange way, we work in the shadows, even though we have a legal business. There’s a lot of cash movement as you’re not allowed to use credit cards in the United States. Mainstream banking, like Santander or Barclays isn’t available to us so we tend to work with local credit unions. Even if we move money across state lines, that’s a violation of federal law.
CH: Why is Lesotho such a hotbed for cannabis manufacturing?
KS: Our roots as a company in the United States are in the Emerald triangle, an area north of Napa Valley, to the south of Grants Pass in Oregon and up and down the spine of what’s known as the 101 Highway.
This is where 90 percent of all cannabis in North America was supplied prior to legalisation. What the Carolinas are to tobacco and the Great Plains are to wheat, the Emerald Triangle is to cannabis
Lesotho, which is the Emerald triangle of Africa, has always been the place where cannabis has flourished. It has always been the breadbasket of cannabis in Africa.
A couple of years ago, the deputy prime minister [of Lesotho] said that when they were fighting apartheid, they said, ‘give us our land, our freedom and our cannabis’; that was their cry.
And they were one of the first states in Africa to INCB [International Narcotics Control Board] certification for exportation of cannabis. A lot of large companies piled in after that. I remember the valuations were preposterous and it became very hot.
CH: What drew you to Lesotho and working with Bophela Bioscience?
KS: We have a gorgeous site and arguably one of the largest sites in the country, but what really attracted us to Lesotho was our chairperson, Louisa Mojela, who’s such a force for social good.
10 percent of our profits are going to the local people, the land is owned by a trust for the benefit of the people, and Louisa is really big on the empowerment of the disadvantaged. She also operates her own private equity fund, which is for the empowerment of women in Africa.
Louisa and my partner Andreas Met are really driving the charge in Africa.
The concept is to uses good agricultural collection practices to produce cannabis and then take that cannabis and export it into Malta and inevitably the UK.
CH: Would you consider expanding into other regions in Africa?
KS: Our mantra is do one site, do it well, and don’t diversify. But that being said, given the geography of Lesotho [a mountainous region ideal for growing the Indica cannabis plant], you could see yourself looking towards Ghana or Gambia; somewhere more equatorial where you would put up a grow with a genetic bank dominated more by sativa.
I think that’s more of a longer-term view, because you can still grow a good genetic bank in Lesotho.
I’m hearing that Ghana now is legalising, the Congo is legalising, but they have a way to go to get INCB certification which takes a couple of years.
CH: Have you faced any barriers in Africa due to the pandemic?
KS: We are growing and storing cannabis in Africa and we are getting what’s known as Good Agricultural and Collection Practices (GACP) certification. We’re fairly close to it, but COVID has been a little bit of a setback as the whole South African region is under a very stringent lockdown given this new variant that’s floating around.
And the UK, where a lot of our people are based, is also locked down due to COVID. It’s become really difficult. Right now, what we’re dealing with is even though we’re growing, we’re dealing with practical problems.
For instance, there’s not enough steel in South Africa. South Africa typically would import steel but those imports are not as plentiful as usual. We are not able to complete our certifications because of practical issues like this.
CH: How about in the US and Europe?
KS: We’re starting to see tremendous growth in cannabis in the US as a result of COVID, whereas abroad, it’s disrupted supply chains.
Where COVID has been a boom in the United States, it’s been a curse in the UK and has now been derailed to some degree. But I think inevitably, as we all get our jabs, and everything settles down over the next nine months, I think we’re going to start seeing an incredible flourish of international trade in cannabis.
I could envision the Biden regime entering international cannabis trade, too. It’s conceivable within the next two years that you’ll start to see cannabis flowing from Africa into the United States.
CH: What is your view of the UK cannabis market?
KS: We’re one of five licensed medical distributors and the name of our company in the UK is Canmart, which started its journey about two years ago.
One thing that’s interesting about the UK market is that it has a very active black market with high per capita consumption rate of cannabis; one of the highest in the world.
It [the UK] is sort of like California before legalisation, during what we call the ‘medical days’. The UK is starting the medical days right now.
What’s happening is you’re starting to see liberalisation, even under this Conservative government, of medicinal cannabis. The tipping point will come when the NHS starts allowing certain groups to be reimbursed for cannabis. That to me is the point where it’ll become medically available for many different people.
CH: What are Halo Labs’ plans for the UK?
KS: Under the current regime, cannabis in the UK has to be imported, so the goal is to get the Lesotho operation qualified for imports into the UK.
The UK is allowing cannabis to come in from abroad, but that cannabis has to have a certification of cGMP (current good manufacturing practices) which is a medicinal certification. We have a partner in Malta – we import GACP cannabis into Malta and there they make it into Medicinal Products for EU certification, which is then imported into the UK.
It will be interesting to see what happens now with the UK’s separation from the EU.
CH: What trends can you see on the horizon?
KS: Outside North America is where it’s hot right now in terms of cannabis. Brazil is now liberalising, Colombia, Uruguay and Mexico has liberalised and on the African continent, multiple countries are starting to liberalise.
I think you’re going to start to see this flourish of international trade in cannabis.
I also think we’re going to start to seeing more countries develop recreational regimes, and I think it’s going to come faster than people anticipate.
Vice President-elect, Kamala Harris, in her debate with Pence said that one of their initiatives is going to be the descheduling of cannabis so it’s no longer considered a controlled substance.
I could even see the UK’s Conservative government following a US lead over the next year or two. I see the softening of his [Boris Johnson’s] position, so I can see this liberalisation really starting to snowball.
The alcohol industry is seeing diminished growth as a result of the cannabis industry’s growth.
Isle of Man launches medical cannabis export sector
The Isle of Man is open for business to the medical cannabis industry.
The Isle of Man government has declared it is open for business to the medical cannabis industry.
In a big to create 250 new jobs and generate £3 million a year for the island, policymakers want it to become ‘a world-leading exporter’.
Applications are now open for licences to produce and distribute treatments on the island, as well as to use it as an export base.
The island’s regulator – the Gambling Supervision Commission – has set out conditions for the licensing of high-THC cannabis and hemp.
Enterprise minister Laurence Skelly said: “The growing global medicinal cannabis market provides significant opportunity for economic development in the Isle of Man, and the new regulatory framework and guidance will offer stringent and flexible licensing of a broad range of cannabis products, which ranges from outdoor grown industrial hemp to indoor grown medicinal products.
“The Isle of Man Government has every confidence that the GSC will provide a world class regulatory structure required to regulate this new and complex industry.
“I am delighted to welcome licence applications and look forward to attracting quality businesses to the Island, transforming the cannabis export sector into a key contributor to the Isle of Man’s post-Covid economic recovery.”
The self-governing British Crown Dependency, which has a population of 83,000, approved new medical cannabis laws in January.
The island’s parliament – the Tynwald – moved to attract the industry to its shores after a public consultation showed 95 percent of residents were in favour of the policy.
Mark Rutherford, director of policy at the island’s regulator, said: “The GSC already has a sophisticated framework for supervising gambling.
‘We have worked carefully to apply the best of that framework to the risks in the new sector and we have educated ourselves in the technical areas that are new to us.
“As regulators, we aspire to put our regulatory umbrella above as many consumers as possible so that they can benefit from regulations that are well thought out and properly supervised.
“Years of prohibition mean that the markets in which our licensees will be participating are still in their infancy and still contain many uncertainties.
“To address this situation, it is our aim to ensure that consumers who purchase Isle of Man products will be able to understand exactly what their product contains through accurate labelling and independent testing.
“The GSC recognises there are many stakeholders in this newly created field and intends to extend its ethos of cooperation with other government authorities into its approach to cannabis regulation.”
Always Pure Organics announces major expansion to meet demand
Construction is underway on a new 10,000 square foot warehouse
Always Pure Organics has announced that construction is underway on its new 10,000 square foot warehouse as part of a major expansion, here they reveal all.
At Always Pure Organics, our mission is to accelerate the global access, acceptance and understanding of cannabinoids and their wide benefits.
We’re proud to take you ‘behind the scenes’, where you’ll meet our team and gain a further understanding of how we serve our clients and facilitate growth of the cannabinoid industry.
One of our latest projects involves expanding our Always Pure Organics facilities. Renovations began in early June and we are excited for the extra space that the expansion will afford our lab and operation teams.
Our CEO Gavin Ogilvie commented on the project: “We’re so proud of the growth we’ve achieved. In two and a half years the business has gone from three people working out of a bedroom to over 50 team members servicing 500 global clients.
“With this comes a responsibility to our customers and partners to continue to deliver the personal, quick and hands-on service that we have done historically. With the increasing demand placed on our operations and production teams this was becoming a mounting challenge. Therefore, we have invested heavily to overhaul and upsize our warehouse and clean rooms. This week we began the construction in our new 10,000 square foot warehouse.
“We want to offer the best products, with more variety, more quickly and with a better user experience than any of our competitors. This is just one step in achieving that.”
Always Pure Organics Specialist Manufacturer of Cannabis Based Products.
We offer the highest quality wholesale legal cannabis and cannabinoid products, as bulk ingredients, bulk products, white label, and bespoke formulations. This is coupled with regulatory and legal expertise and supported by delivery globally.
Our unique bespoke formulation products allow our customers to create their own product from scratch, whilst we provide the regulatory and product knowledge, as well as production of the product.
The UK cannabis veterans taking on the industry’s big beasts
AltoVerde wants to shake things up in the industry which it believes has gone from counter-culture to corporate.
Meet the UK executive and cannabis veteran, aiming to take on Europe and North America’s established industry titans.
Mitesh Makwana is the director of AltoVerde, a start up company looking to establish itself as one of the continent’s big players.
The race is on to put roots down in Europe with several countries expected to expand patient access in the coming years – and even open up adult use markets.
Huge companies from across the pond like Tilray, Aurora and Bedrocan have already got boots on the ground, buying up companies and starting operations in places like Denmark and Portugal.
AltoVerde is aiming to be the new kid on the block and wants to shake things up in an industry which it believes has gone from counter-culture to corporate.
Makwana told Cannabis Health: “It’s become a completely different scene. We know that there might be a view that us industry veterans aren’t ready to take on this new market but we just plan to get our heads down and get on with what we know best.
“We understand that there are big regulatory hurdles, but ultimately there is one goal: getting a good end product to consumers at a fair price.”
This team of ‘veterans’, some of whom have almost two decades experience in the industry, have been in the game since paraphernalia and souvenir seeds were the only way to make money out of cannabis in Europe.
But things are changing. The medical cannabis sector in Europe is forecast to explode over the next few years and companies set up and ready to go when liberalisation happens stand to make a fortune.
Makwana said: “The team and our roots set us apart from the rest of the industry.
“Many of the people involved with company have been active in this sector for several years, people who’ve spent years honing their expertise in cultivation, breeding, plantation management, clinical trials, chemistry and extraction.
“This plant has a lot of amazing properties and we’re passionate about unlocking them for consumers and patients.”
The company has already completed an initial funding round and is planning a private subscription to raise further capital in the near future.
Deals to begin two manufacturing operations in Europe, including a 10,000+ square metre cultivation plant in Macedonia, are nearing completion and the company has longer term ambitions to carry out its own clinical trials.
It’s early days but the company has set out a five-year growth plan and is targeting £13.1m in inward investment.
Makwana told Cannabis Health, AltoVerde, which is headquartered in the UK, will be involved from seed to distribution and will respond to change in the market and regulations.
He said: “We’re setting ourselves up to be able to adjust to the way market demands shift over the coming years.
“With our expertise we know we can satisfy demand from the medicinal and wellbeing markets.
“We’re positioning ourselves up to take advantage whichever way regulations go and however the market changes.
“With our experience we know we can change and adapt.”
Introducing our new B2B title
- Weekend digest: Six big stories from the cannabis world you might have missed
- New tracking app launches for UK medical cannabis patients
- Isle of Man launches medical cannabis export sector
- The CBD brand helping black women love their natural hair
- “I could be a better father with cannabis as my medicine”
- Washington offers free cannabis to boost Covid-19 vaccine uptake
News11 months ago
NHS lines up cannabis medicine manufacturing
News7 months ago
Community extends support to cannabis icon Rick Simpson
Case Studies1 year ago
CBD oil and fibromyalgia – a case study
News9 months ago
Cancer survivor claims cannabis oil helped her beat brain tumour
Feature12 months ago
Medical cannabis could help long-term effects of COVID-19, says David Nutt
Insight8 months ago
I’ve gone from a wheelchair to walking thanks to cannabis
Industry5 months ago
“Game changer” for the sector: First cannabis company expected to list on LSE next month
News9 months ago
“I’m not a bad person” – chronically ill woman convicted of growing medical cannabis